154 related articles for article (PubMed ID: 20032435)
1. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
Ohno S; Kyo S; Myojo S; Dohi S; Ishizaki J; Miyamoto K; Morita S; Sakamoto J; Enomoto T; Kimura T; Oka Y; Tsuboi A; Sugiyama H; Inoue M
Anticancer Res; 2009 Nov; 29(11):4779-84. PubMed ID: 20032435
[TBL] [Abstract][Full Text] [Related]
2. Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
Ohno S; Takano F; Ohta Y; Kyo S; Myojo S; Dohi S; Sugiyama H; Ohta T; Inoue M
Anticancer Res; 2011 Jul; 31(7):2447-52. PubMed ID: 21873158
[TBL] [Abstract][Full Text] [Related]
3. Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.
Coosemans A; Vergote I; Van Gool SW
Expert Rev Clin Immunol; 2014 Jun; 10(6):705-11. PubMed ID: 24784346
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
Morita S; Oka Y; Tsuboi A; Kawakami M; Maruno M; Izumoto S; Osaki T; Taguchi T; Ueda T; Myoui A; Nishida S; Shirakata T; Ohno S; Oji Y; Aozasa K; Hatazawa J; Udaka K; Yoshikawa H; Yoshimine T; Noguchi S; Kawase I; Nakatsuka S; Sugiyama H; Sakamoto J
Jpn J Clin Oncol; 2006 Apr; 36(4):231-6. PubMed ID: 16611662
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
6. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
Nakajima H; Kawasaki K; Oka Y; Tsuboi A; Kawakami M; Ikegame K; Hoshida Y; Fujiki F; Nakano A; Masuda T; Wu F; Taniguchi Y; Yoshihara S; Elisseeva OA; Oji Y; Ogawa H; Azuma I; Kawase I; Aozasa K; Sugiyama H
Cancer Immunol Immunother; 2004 Jul; 53(7):617-24. PubMed ID: 15175906
[TBL] [Abstract][Full Text] [Related]
7. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Dohi S; Ohno S; Ohno Y; Takakura M; Kyo S; Soma G; Sugiyama H; Inoue M
Anticancer Res; 2011 Jul; 31(7):2441-5. PubMed ID: 21873157
[TBL] [Abstract][Full Text] [Related]
8. [WT1 peptide-based immunotherapy].
Sugiyama H
Nihon Rinsho; 2005 Jun; 63(6):1101-9. PubMed ID: 15948398
[TBL] [Abstract][Full Text] [Related]
9. [WT1-targeting cancer vaccine].
Sugiyama H
Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381
[TBL] [Abstract][Full Text] [Related]
10. WT1 peptide vaccine for the treatment of cancer.
Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
[TBL] [Abstract][Full Text] [Related]
11. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
Tsuboi A; Oka Y; Udaka K; Murakami M; Masuda T; Nakano A; Nakajima H; Yasukawa M; Hiraki A; Oji Y; Kawakami M; Hosen N; Fujioka T; Wu F; Taniguchi Y; Nishida S; Asada M; Ogawa H; Kawase I; Sugiyama H
Cancer Immunol Immunother; 2002 Dec; 51(11-12):614-20. PubMed ID: 12439606
[TBL] [Abstract][Full Text] [Related]
12. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.
Sugiyama H
Jpn J Clin Oncol; 2010 May; 40(5):377-87. PubMed ID: 20395243
[TBL] [Abstract][Full Text] [Related]
13. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
[TBL] [Abstract][Full Text] [Related]
14. Defining MHC class II T helper epitopes for WT1 tumor antigen.
Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
[TBL] [Abstract][Full Text] [Related]
15. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
Sugiyama H
Expert Rev Vaccines; 2005 Aug; 4(4):503-12. PubMed ID: 16117707
[TBL] [Abstract][Full Text] [Related]
17. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
Tsuboi A; Oka Y; Osaki T; Kumagai T; Tachibana I; Hayashi S; Murakami M; Nakajima H; Elisseeva OA; Fei W; Masuda T; Yasukawa M; Oji Y; Kawakami M; Hosen N; Ikegame K; Yoshihara S; Udaka K; Nakatsuka S; Aozasa K; Kawase I; Sugiyama H
Microbiol Immunol; 2004; 48(3):175-84. PubMed ID: 15031530
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
Ohno S; Okuyama R; Aruga A; Sugiyama H; Yamamoto M
Anticancer Res; 2012 Jun; 32(6):2263-9. PubMed ID: 22641661
[TBL] [Abstract][Full Text] [Related]
19. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.
Coosemans A; Wölfl M; Berneman ZN; Van Tendeloo V; Vergote I; Amant F; Van Gool SW
Anticancer Res; 2010 Sep; 30(9):3709-14. PubMed ID: 20944158
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]